Innovation and breakthrough of Fosun medicine and bio medicine: the clinical application of Fosun Hanlin bio modified monoclonal antibody has been approved in three places on both sides of the Taiwan Strait

On October 14, 2016, the latest A-share announcement issued by Fosun Pharmaceutical showed that its holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd (hereinafter referred to as "Fuhong Hanlin") was in the process of developing two new injectable drugs, which were approved by the State Food and Drug Administration (hereinafter referred to as "the State Food and Drug Administration") for clinical trials Among them, EGFR humanized monoclonal antibody injection (hereinafter referred to as "simplified") It is also approved by food and Drug Administration (FDA) for clinical trials In addition, another holding subsidiary of Fosun Pharmaceutical, Dalian yalifeng biopharmaceutical Co., Ltd (hereinafter referred to as "Dalian yalifeng") has also received the drug registration approval for human rabies vaccine (Vero cell) approved and issued by the State Food and drug administration Among the three new injectable drugs approved for clinical trials, the new hlx07 drug developed by Fuhong Hanlin was approved for clinical trials of colorectal cancer and other solid cancer indications At present, Fuhong Hanlin's new hlx07 drug has been approved in three places, namely, mainland China, Taiwan and the United States Among them, the application progress in Taiwan is the fastest, and the clinical approval has been obtained in June this year This project is the first innovative bio modified monoclonal antibody of Fuhong Hanlin, which has realized the research and development leap of Fuhong Hanlin from bio similar drug to innovative bio modified drug with completely independent intellectual property rights, and achieved the international strategy of R & D products through clinical application in three places Another new drug approved this time also came from Fuhong Hanlin, whose self-developed recombinant anti EGFR human mouse chimeric monoclonal antibody injection was approved for clinical trials of head and neck squamous cell carcinoma indications In August 2016, the new drug was approved by the State Food and Drug Administration for clinical trials of indications for metastatic colorectal cancer This time, the second indication test of the new drug was approved In addition, the human rabies vaccine (Vero cell) independently developed by Dalian yalifeng, another holding subsidiary of Fosun Pharmaceutical, is also among the approved clinical trials The new drug is suitable for the prevention of rabies, and can stimulate the body to produce anti rabies virus immunity after vaccination Fosun Pharmaceutical always takes independent innovation as the source power of enterprise development, and continuously improves the pharmaceutical R & D innovation system of "combination of imitation and innovation" In recent years, Fosun Pharmaceutical continues to increase R & D investment, and has formed an international R & D layout and strong R & D capabilities At present, Fosun Pharmaceutical and its holding subsidiaries have nearly 900 R & D personnel By establishing an interactive and integrated R & D system in Shanghai, Chongqing, Taipei, and San Francisco, the company has continuously increased investment in four R & D platforms, and has built an efficient R & D platform in the fields of small molecule chemical innovative drugs, large molecule biological drugs, high-value generic drugs, and special preparation technologies.